Nippon Shinyaku Co., Ltd. (NPNKF)
OTCMKTS · Delayed Price · Currency is USD
25.58
0.00 (0.00%)
Jul 15, 2025, 4:00 PM EDT
Nippon Shinyaku Revenue
In the fiscal year ending March 31, 2025, Nippon Shinyaku had annual revenue of 160.23B JPY with 8.08% growth. Nippon Shinyaku had revenue of 38.91B in the quarter ending March 31, 2025, with 9.53% growth.
Revenue
160.23B JPY
Revenue Growth
+8.08%
P/S Ratio
1.30
Revenue / Employee
71.44M JPY
Employees
2,243
Market Cap
1.39B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 160.23B | 11.98B | 8.08% |
| Mar 31, 2024 | 148.26B | 4.08B | 2.83% |
| Mar 31, 2023 | 144.18B | 6.69B | 4.87% |
| Mar 31, 2022 | 137.48B | 15.60B | 12.80% |
| Mar 31, 2021 | 121.89B | 5.25B | 4.50% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| Glass House Brands | 215.62M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |